... hormone receptor (HR)-positive, HER2-negative breast cancer, according to research presented at the San Antonio Breast Cancer Symposium 2022.
News
- Cemiplimab Plus REGN3767 and Chemo Shows Promise for HER2- Breast Cancer
- Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial
... colleagues at the 2022 San Antonio Breast Cancer Symposium (Abstract GS3-01). ... Gilead Sciences, Novartis, Pfizer, and Puma Biotechnology.
- Texas Children's Hospital announces plan to tackle mental health crisis | TPR
San Antonio soccer fans join the Men's World Cup's global audience · Union members and allies stand in support of Starbucks workers at a rally at ...
- Germline PVs in BRCA1/2, CHEK2 Linked to Higher Risk of Contralateral Breast Cancer
... to research presented at the San Antonio Breast Cancer Symposium 2022. ... Disclosures: Some study authors declared affiliations with biotech, ...
- Celcuity Presents Updated Resu - GuruFocus.com
... Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium ... a clinical-stage biotechnology company focused on development of ...